Virally Mediated Gene Therapy For The Control Of Chronic Or Persistent Pain


Current treatments for pain, especially chronic pain, are only partially effective and can eventually involve procedures that are invasive or associated with unacceptable side effects. In vivo gene transfer could be used to directly modulate pain and provide a long-term pain control. This invention describes a method of using an adenovirus or an adeno-associated virus that are genetically engineered to deliver DNA encoded peptides or proteins to neurons involved in the transmission of pain. The invention provides for a novel means to treat chronic pain by administering a beta-endorphin-expressing recombinant adenovirus into the subarachnoid space. The recombinant virus infects the pia mater connective tissue cells and the infected cells express the fusion protein, wherein the fusion protein is cleaved and the neuroactive product is secreted into spinal cord parenchymal tissue in an amount effective to treat the chronic pain but not significantly affecting basal nociceptive responses. The invention demonstrates a gene transfer approach to treatment of chronic pain disorders or cancer pain, and may be generalized to spinal cord injury or neurodegenerative disorders.

Inventors:

Michael Iadarola (NIDCR)  ➽ more inventions...

Robert Caudle (NIDCR)  ➽ more inventions...

Alan Finegold (NIDCR)  ➽ more inventions...

Andrew Mannes (NIDCR)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 6,596,269 issued 2003-07-22
PCT Application No. PCT/US99/22103
US Application No. 09/787,660

Licensing Contact:
David Bradley,
Email: bradleyda@nidcr.nih.gov
Phone: 301-402-9242

OTT Reference No: E-044-1998-0
Updated: May 6, 2018